News Sentiment

SCNX sentiment intelligence

Scienture Holdings, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 41 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Pharmaceutical Retailers Read-through group
Latest close 0.37 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+7.6% over one week, -2.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Scienture Holdings Company Profile & Introduction

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 7.6% Price confirming higher
Trend fit Trend inactive -2.1% over four weeks
Fair value -89.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 20
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 6
TradingView 5
Moomoo 4
GlobeNewswire 3
The Globe and Mail 2
marketscreener.com 2
GuruFocus 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 8
Analyst action 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 41
Quartr Direct company coverage

Scienture Holdings (SCNX) Registration filing Summary

Scienture Holdings (SCNX) filed a registration summary outlining its strategic shift from a digital pharmacy marketplace to a specialty pharmaceutical company, focusing on CNS and cardiovascular diseases. The company reported a net loss of $4.4 million for the six months ending J

Tone
Negative 34/100
Event
Market update
Published
11 Jul 2026 23:12
Source
Quartr
The Globe and Mail Direct company coverage

Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)

Two analysts have issued bullish sentiments on healthcare stocks Scienture Holdings (SCNX) and Royalty Pharma (RPRX). Maxim Group analyst Naz Rahman reiterated a Buy rating on Scienture Holdings with a $1.50 price target, while Bank of America Securities analyst Jason Gerberry ma

Tone
Neutral 50/100
Event
Analyst action
Published
11 Jul 2026 22:47
Source
The Globe and Mail
Sahm Direct company coverage

Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why

Scienture Holdings (NASDAQ: SCNX) shares surged over 20% pre-market due to the impending commercial launch of its high-dose naloxone nasal spray, REZENOPY, with shipments to wholesalers expected this month and retail availability in August. This follows a previous successful prod

Tone
Positive 71/100
Event
Market update
Published
11 Jul 2026 13:40
Source
Sahm
Investing.com Direct company coverage

Scienture completes manufacturing for naloxone spray launch

Scienture Holdings Inc. has completed manufacturing of REZENOPY naloxone hydrochloride nasal spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers this month, with commercial availability expected in August. The FDA-approved product targets a U.S. naloxone marke

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 12:40
Source
Investing.com
www.marketscreener.com Direct company coverage

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

SCIENTURE Holdings, Inc. has finished manufacturing commercial inventory for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July. This marks a significant commercial milestone for the company, with REZENOP

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 11:40
Source
www.marketscreener.com
Moomoo Direct company coverage

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers

SCIENTURE Holdings, Inc. announced that it has completed manufacturing of its commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later in July 2026. Commercial availability for purchase i

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 11:40
Source
Moomoo
Stock Titan Direct company coverage

Scienture readies highest-dose naloxone spray for August sale

Scienture (NASDAQ: SCNX) has completed the commercial launch inventory for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. wholesalers in July 2026, with commercial availability expected in August. REZENOPY is the highest-dose FDA-approved na

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 11:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Scienture Holdings, Inc. – NASDAQ:SCNX

The article displays the "Price to sales forward" metric for Scienture Holdings, Inc. (NASDAQ: SCNX) on the TradingView platform. It provides a financial metric for the company, accessible through various market data and analysis tools. The page itself is a snapshot of financial

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 17:42
Source
TradingView
TradingView Direct company coverage

Price to book forward of Scienture Holdings, Inc. – NASDAQ:SCNX

This article mentions the "Price to book forward" for Scienture Holdings, Inc. (NASDAQ: SCNX). It appears to be a stub or a title for a financial data point without further textual analysis or details provided. The content primarily consists of navigation and copyright informatio

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:27
Source
TradingView
TradingView Direct company coverage

Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX)

This article provides an overview of Scienture Holdings, Inc. (SCNX) financial actuals and estimates, including its current stock price, volatility, market cap, and future earnings reports. It details past stock performance, analyst forecasts, and answers frequently asked questio

Tone
Negative 35/100
Event
Earnings
Published
25 Jun 2026 18:11
Source
TradingView
TradingView Direct company coverage

SCNX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Scienture Holdings, Inc. (SCNX) stock. An analyst has set a 1-year price target of $1.50, though the stock has seen significant declines over the past year. The article also includes financial data, earnings information, and a

Tone
Negative 37/100
Event
Analyst action
Published
25 Jun 2026 14:10
Source
TradingView
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Scienture Holdings Inc (SCNX), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. It notes that SCNX's stock price is trading between resistance at $0.43 and support at $0

Tone
Negative 14/100
Event
Market update
Published
24 Jun 2026 15:09
Source
TradingKey
Simply Wall Street Direct company coverage

Scienture Holdings (Nasdaq:SCNX) - Stock Analysis

This article provides a stock analysis of Scienture Holdings (Nasdaq: SCNX), highlighting its undervaluation, forecast earnings growth, and risks such as shareholder dilution and volatile share price. It details recent commercialization efforts for its drug Arbli and FDA-approved

Tone
Neutral 50/100
Event
Earnings
Published
21 Jun 2026 02:09
Source
Simply Wall Street
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Scienture Holdings Inc (SCNX), highlighting its current valuation score of 8.95 within the Pharmaceuticals industry. It details the company's P/E ratio, noting it is significantly below its recent high. The article also mentions that

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 01:39
Source
TradingKey
Investing.com Nigeria Direct company coverage

Scienture stock rises after adding 12.5M covered lives for Arbli

Scienture Holdings Inc (NASDAQ: SCNX) shares rose 5.8% after announcing additional payor coverage for its drug Arbli, a losartan potassium oral suspension. This expanded coverage adds approximately 12.5 million covered lives through Medicare Part D and other healthcare channels,

Tone
Positive 72/100
Event
Market update
Published
19 Jun 2026 00:39
Source
Investing.com Nigeria
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Institutional Confidence

This article from TradingKey provides an overview of the institutional confidence in Scienture Holdings Inc (SCNX), specifically detailing changes in institutional shareholdings. Several individuals and firms, including Narasimhan (Mani), Hariharan (Shankar Ph.D.), and Geode Capi

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 13:10
Source
TradingKey
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Scienture Holdings Inc (SCNX), noting that relevant data for business segments and regional revenue contribution has not yet been disclosed by the company for FY2025 and earlier quarters. It highlights that the company's stock closed a

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 12:39
Source
TradingKey
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

Analysts are split on their ratings for healthcare companies Moderna (MRNA) and Scienture Holdings (SCNX). William Blair analyst Myles Minter reiterated a Hold rating for Moderna, while Maxim Group analyst Naz Rahman reiterated a Buy rating for Scienture Holdings with a $1.50 pri

Tone
Neutral 50/100
Event
Analyst action
Published
18 Jun 2026 12:39
Source
The Globe and Mail
Investing.com Direct company coverage

Scienture expands payor coverage for Arbli by 12.5M lives

Scienture Holdings Inc. has announced a significant expansion in payor coverage for its oral suspension, Arbli, adding approximately 12.5 million covered lives through Medicare Part D supplement plans and other commercial and government healthcare channels. This move aims to incr

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 12:10
Source
Investing.com
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis

Scienture Holdings Inc (SCNX) currently holds a financial score of 6.07, ranking 148th out of 157 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company recently reported a quarterly revenue of 56.33K, marking a significant y

Tone
Positive 62/100
Event
Earnings
Published
18 Jun 2026 06:10
Source
TradingKey
Moomoo Direct company coverage

SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

SCIENTURE has significantly expanded payor coverage and commercial access for its medication, Arbli, adding approximately 12.5 million covered lives across the nation. This expansion includes new agreements with major payors like Capital Blue Cross in Pennsylvania and Excellus Bl

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 06:09
Source
Moomoo
TradingKey Direct company coverage

Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Scienture Holdings Inc (SCNX) currently holds an earnings forecast score of 8.00, placing it 55th out of 157 in the Pharmaceuticals industry. Based on analysis from one analyst, the stock has a "Buy" rating with an upside potential of 292.67%. The company's expected revenue for t

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 05:10
Source
TradingKey